PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study.
- Author:
Xin-Xing DU
1
;
Yan-Hao DONG
1
;
Han-Jing ZHU
1
;
Xiao-Chen FEI
1
;
Yi-Ming GONG
1
;
Bin-Bin XIA
1
;
Fan WU
1
;
Jia-Yi WANG
1
;
Jia-Zhou LIU
1
;
Lian-Cheng FAN
1
;
Yan-Qing WANG
1
;
Liang DONG
1
;
Yin-Jie ZHU
1
;
Jia-Hua PAN
1
;
Bai-Jun DONG
1
;
Wei XUE
1
Author Information
- Publication Type:Journal Article
- Keywords: anlotinib; ctDNA; immune checkpoint inhibitor; programmed cell death-1 inhibitor; prostate cancer
- MeSH: Male; Humans; Prostate-Specific Antigen; Treatment Outcome; Prostatic Neoplasms, Castration-Resistant/drug therapy*; Immune Checkpoint Inhibitors/therapeutic use*; Retrospective Studies
- From: Asian Journal of Andrology 2023;25(2):179-183
- CountryChina
- Language:English
- Abstract: Management and treatment of terminal metastatic castration-resistant prostate cancer (mCRPC) remains heavily debated. We sought to investigate the efficacy of programmed cell death 1 (PD-1) inhibitor plus anlotinib as a potential solution for terminal mCRPC and further evaluate the association of genomic characteristics with efficacy outcomes. We conducted a retrospective real-world study of 25 mCRPC patients who received PD-1 inhibitor plus anlotinib after the progression to standard treatments. The clinical information was extracted from the electronic medical records and 22 patients had targeted circulating tumor DNA (ctDNA) next-generation sequencing. Statistical analysis showed that 6 (24.0%) patients experienced prostate-specific antigen (PSA) response and 11 (44.0%) patients experienced PSA reduction. The relationship between ctDNA findings and outcomes was also analyzed. DNA-damage repair (DDR) pathways and homologous recombination repair (HRR) pathway defects indicated a comparatively longer PSA-progression-free survival (PSA-PFS; 2.5 months vs 1.2 months, P = 0.027; 3.3 months vs 1.2 months, P = 0.017; respectively). This study introduces the PD-1 inhibitor plus anlotinib as a late-line therapeutic strategy for terminal mCRPC. PD-1 inhibitor plus anlotinib may be a new treatment choice for terminal mCRPC patients with DDR or HRR pathway defects and requires further investigation.
